Results 91 to 100 of about 38,260 (253)

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer, Tom P. Freeman, Martine Skumlien, Esther Walton, Thomas Lancaster, Jorien L. Treur, Valentina Lorenzetti, Anna K. M. Blackwell, Chloe Burke, Richie J. Carr, Constantinos Constantinides, Maisie Cox, Sarah Dance, Shadi Daryan, Sorcha Hamilton, Tom Jenkins, Gemma M. J. Taylor   +16 more
wiley   +1 more source

Proportions and correlates of high‐risk cannabis use in Australia—A cross‐sectional analysis of the 2022–2023 National Drug Strategy Household Survey

Addiction, EarlyView.
Abstract Background and aim Cannabis use is prevalent in Australia, however, limited research has explored the levels of high‐risk cannabis use within nationally representative samples. This study aimed to address this gap by examining the proportion of individuals meeting criteria for high‐risk cannabis use and identifying its correlates in a ...
Janni Leung, Daniel Stjepanović, Gary Chung Kai Chan, Wayne Denis Hall, Danielle Dawson   +4 more
wiley   +1 more source

Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling

Addiction, Volume 120, Issue 4, Page 686-687, April 2025.
Rachel Lees Thorne, Tom P. Freeman
wiley   +1 more source

A call for action: Closing the evidence gap in management of stimulant‐induced psychosis

Addiction, EarlyView.
Abstract Background Stimulant‐induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant‐related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two
Anne Bouthillier, Heidar Sharafi, Adam Bisaga, Didier Jutras‐Aswad   +3 more
wiley   +1 more source

Cannabis Use and Its Interaction with Anxiety Disorders

European Psychiatry
Introduction Cannabis use has been reported to cause a myriad of acute adverse reactions, including those linked to anxiety disorders, such as panic attacks and derealization.
F. Varino, T. Duarte, F. S. Silva, P. Froes, A. M. Fernandes, P. Baronet   +5 more
doaj   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder.

PLoS ONE
BackgroundAs cannabis legalization continues to spread across the United States, average Δ9-tetrahydrocannabinol concentrations in recreational products have significantly increased, and no prior study has evaluated effective treatments to reduce ...
L Cinnamon Bidwell, Renee Martin-Willett, Samantha N Melendez, Luiza Rosa, Gregory Giordano, Kent E Hutchison, Angela D Bryan   +6 more
doaj   +1 more source

Cannabis use and cannabis use disorders and their treatment in the Europe

European Archives of Psychiatry and Clinical Neuroscience
Abstract This paper introduces the special issue on cannabis use in Europe. It describes data on the prevalence of cannabis use in Europe and the more limited data on the prevalence of cannabis use disorders, one of the most common forms of drug problem treated in many countries in Europe.
Wayne Hall, Jakob Manthey, Daniel Stjepanović   +2 more
openaire   +3 more sources

The association between sleep disturbance and stimulant use: A cross‐lagged examination

Addiction, EarlyView.
Abstract Background and aims Sleep disruptions increase the risk of substance misuse. Substance use—especially stimulants—can increase acute and chronic sleep dysfunction. This study aimed to estimate the associations between sleep disturbance and stimulant use over time among participants with stimulant use disorder (StUD).
Viviana E. Horigian, Renae D. Schmidt, Daniel J. Feaster, Rui Duan, Sophia T. Gonzalez, Kathryn Hefner, Dikla Shmueli‐Blumberg, Ashley Vena, Landhing M. Moran, Chloe A. DiCamillo, Shirin Shafazand, Susan Tross, Judith Feinberg   +12 more
wiley   +1 more source

Identification of cannabis use disorder using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5) versus DSM‐5‐proxy measures: Differences by socio‐demographic characteristics

Addiction, EarlyView.
Abstract Background and Aims Cannabis use disorder (CUD) is a pressing public health concern in the United States, and understanding trends in prevalence requires considerations of how changes in measurement influence identification of CUD. Starting in 2021, the National Survey on Drug Use and Health (NSDUH) assessed CUD using all 11 Diagnostic and ...
Evan L. Eschliman, Erin M. Annunziato, Nicole D. Fitzgerald, Pia M. Mauro   +3 more
wiley   +1 more source